Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.revbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2022 | $12.00 | Buy | Roth Capital |
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
3 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from the Phase 1 clinical study of Gemini released on June 24, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240924064564/en/Figure 1. Upregulation of IL-10 at 2 Ho
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the Company on February 5, 2024 (the "Existing Warrants"), at the reduced exercise price of $1.50 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-276232). The closing of the off
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity "The Revelation team has worked hard in the first half of 2024 to continue
-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity- -Gemini was safe and well tolerated at pharmacologically active doses- -Phase 1 results enable further development across multiple indications- Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in h
-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy individuals 18 to 55 years of age. The forthcoming top-line data will include primary end points of safety and tolerability along with exploratory endpoints including multiple biomarkers of activity
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its curren
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Corporate Highlights Completed a $6.2 million public offering. Commencement of first in human Phase 1 clinical study of Gemini at the beginning of March. Oral presentation and poster of nonclinical data demonstrating Gemini reduces the severity and duration of acute kidney injury in an ischemia reperfusion model at the 29th International Conference on Advances in Critical Care Ne
– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI) - Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego on March 12-15,
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California. Details regarding the Revelation fireside chat are as follows: 35th Annual Roth Conference Presentation Details Date: Monday, March 18, 2023 Time: 11:00 a.m. Pacific Time Location: The Ritz Ca
-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has commenced a first in human Phase 1 clinical study (RVL-HV02) to evaluate escalating doses of intravenously administered Gemini. The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age. Top-line data including safe
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
10-Q/A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
10-Q/A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
10-K/A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
424B3 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
EFFECT - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
S-3 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity "The Revelation team has worked hard in the first half of 2024 to continue
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its curren
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results. Corporate Highlights Recently released biomarker data demonstrating the pharmacologic activity of Gemini in multiple preclinical studies including: Significant mobilization and upregulation of white blood cells including neutrophils, monocytes and lymphocytes. Significant upregulation of therapeutic cytokines including interleukin-10 (IL-10), neutrophil gelatinase associated lipocalin (NGAL) and
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cas
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted recent corporate progress. Corporate Highlights Established strong scientific advisory team with extensive preclinical experience using PHAD to prevent disease. Initiated additional nonclinical studies to further study PHAD in treatment and prevention of CKD and AKI in order to inform future clinical study designs in patients. IND and clinical enabling studies under way for anticipated Ph
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported first quarter 2022 financial results and highlighted recent corporate progress. Recent Corporate Progress In January we completed our merger with Petra Acquisition, Inc. and started trading on the Nasdaq Capital Market.Also in January, we completed our $7.7 million PIPE financing.We anticipate completing enrollment in the Phase 1b allergen challenge and receiving top-line data from that study during the secon
-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing (877) 815-0146 for domestic callers and (631) 625-3219 for international callers. Please provide the operator with the passcode 1166664 to join the conference call. An
https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07082024_REVB_Sorensen.pdf
On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified. Additionally, statistically significant dose-dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini was observed. The study enrolled 40 healthy individuals 18 to 55 years of age. Administration of Gemini induced significant, dose-dependent changes in key circulatory biomarkers of activity that reflect the expected pharmacology of Gemini-specif
-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe and well tolerated at pharmacologically active doses--Phase 1 results enable further development across multiple indications
Gainers Akso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.43% to $1.27. The company's market cap stands at $1.1 million. CareCloud (NASDAQ:CCLD) stock increased by 10.07% to $2.84. The company's market cap stands at $45.7 million. The company's, Q1 earnings came out 3 days ago. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 9.63% to $3.31. The company's market cap stands at $125.5 million. OneMedNet (NASDAQ:ONMD) shares increased by 7.52% to $0.5. The market value of their outstanding shares is at $11.9 million. Reshape Lif
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate of $(1.77) by 38.98 percent. This is a 83.92 percent increase over losses of $(15.30) per share from the same period last year.
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 32.0% to $1.46. The company's market cap stands at $33.2 million. The company's, Q4 earnings came out 4 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 18.91% to $3.52. The company's market cap stands at $30.9 million. CNS Pharma (NASDAQ:CNSP) shares increased by 18.26% to $0.24. The company's market cap stands at $2.5 million. Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 17.39% to $1.66. The market value of their outstanding shares is at $3.7 million. D
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned. On June 9, 2023, the Company called to order its Annual Meeting. At the Annual Meeting, there were not present in person or by proxy at least a majority of the Company's common stock outstanding as of th
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl disaccharide (PHAD) based technology licensed from Vanderbilt University, previously announced on October 6, 2022. Julia Bohannon, Ph.D. is an Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Ce
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation") announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L 309. At the meeting, the stockholders also approved an increase in the authorized common stock to 500,000,0